Compare State Street SPDR S&P Biotech ETF (XBI) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs YieldMax Universe Fund of Option Income ETFs — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.46, while YieldMax Universe Fund of Option Income ETFs trades at $7.62. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| XBI | YMAX | |
|---|---|---|
Sector | Broad Market / Factor | Income / Options Overlay |
52-Week High | $164.28 | $13.26 |
52-Week Low | $86.92 | $7.27 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
YMAX trades at $7.63, down 1.04% in the past 24 hours, with technical indicators showing a bullish overall signal but bearish moving averages. The fund has announced consistent weekly dividend distributions, though recent news highlights concerns over fee structures impacting payouts. Key support is at $7, with resistance at $8.
The outlook for YMAX hinges on its ability to sustain dividend yields amid fee pressures; opportunities include high income generation, but risks involve cost inefficiencies and market volatility. Analyst sentiment is mixed, balancing yield appeal against structural drawbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
